Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Trading Statement

5 Aug 2009 07:00

RNS Number : 8979W
PuriCore Plc
05 August 2009
 



PuriCore H1 2009 Trading Update 

Record Food Safety Shipments

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 5 August 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces a trading update covering the six months to 30 June 2009. Interim results for this period are expected to be announced on 25 August 2009. 

H1 2009 highlights:

Sales of $19.1 million, a decrease of 2% (an increase of 8% on a constant currency basis) (H1 2008: $19.5 million)

Food Safety sales of $12.6 million, an increase of 16%

Endoscopy sales of $6.1 million, a decrease of 27% (3% on a constant currency basis)

 

Cash balance as at 30 June 2009 of $15.8 million (increased from the cash balance as at 31 March 2009 of $15.6 million as a result of improved working capital and foreign currency)

Q2 operational cashflow positive

H1 operational cash outflow of $2.7 million (H1 2008: $4.8 million)

Debt reduced $2.7 million in H1 ($1.3 million in Q2)

 

Gross profit margins unchanged compared with H1 2008
Operating expense reductions of 14% (12% net of non-cash share compensation, depreciation and amortisation) compared with H1 2008 
Record 6-month shipments of 614 Sterilox Food Safety Systems

Post period-end developments (see separate release issued today):

Acquisition of Labcaire Systems Ltd., a leading UK supplier and manufacturer of endoscope disinfection equipment 

£2 million by way of a Placing through the issue of 10,810,811 Placing Shares at an Issue Price of 18.5 pence per share 

Outlook

PuriCore expects to complete the successful integration of Labcaire Systems into the business this year. The Company anticipates delivering full-year results for legacy PuriCore in line with market expectations for revenue growth and operating expenditure improvement. The Directors believe the Company is well positioned for further growth, and PuriCore will continue to make effective use of its balance sheet, including the strategic use of debt financing for leased systems.

Greg Bosch, Chief Executive of PuriCore, said:

 

"Wremain confident that we are well-positioned to execute on our legacy PuriCore business plan and look forward to integrating the Labcaire business in the UK as announced separately today."

Enquiries:

Ben Brewerton

Greg Bosch, CEO

Susan Quigley

Darren Weiss, VP of Finance

Financial Dynamics

PuriCore

+44 (0) 20 7831 3113

+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficileE.coli, HIV, Human and Animal Influenza (including H5N1 Avian Influenza), Legionella, MRSAM.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEASPSESFNEEE
Date   Source Headline
31st Jan 20139:00 amRNSTotal Voting Rights
17th Jan 20135:22 pmRNSHolding(s) in Company
17th Jan 20134:44 pmRNSHolding(s) in Company
17th Jan 20134:42 pmRNSHolding(s) in Company
17th Jan 20134:37 pmRNSHolding(s) in Company
17th Jan 20134:33 pmRNSHolding(s) in Company
17th Jan 20134:25 pmRNSHolding(s) in Company
17th Jan 20134:24 pmRNSHolding(s) in Company
10th Jan 20134:53 pmRNSBoard Changes
10th Jan 20134:36 pmRNSResult of General Meeting
19th Dec 20123:25 pmRNSPublication of Prospectus
19th Dec 20127:00 amRNSRestructuring of Loan Notes and Placing
19th Nov 20127:00 amRNSInterim Management Statement
15th Nov 20127:00 amRNSLohas partnering agreement
9th Oct 20127:00 amRNSPuriCore Signs Two Major US Deals
3rd Oct 20127:00 amRNSPositive Results from ActiVita Research
15th Aug 20122:34 pmRNSBlocklisting Application
13th Aug 20121:07 pmRNSBlocklisting Interim Review
8th Aug 20121:53 pmRNSNotification of Executive Chairman's Option Grant
6th Aug 20127:00 amRNSHalf Yearly Report
26th Jul 20127:00 amRNSNotice of Results
26th Jun 201211:54 amRNSHolding(s) in Company
25th Jun 20129:00 amRNSDirector's Dealing
12th Jun 201211:36 amRNSResult of AGM
30th May 20127:00 amRNSBoard and Organisational Changes
21st May 20127:00 amRNSAnnual Information Update
30th Apr 20127:00 amRNSDirector Dealing and Share Option Grant
26th Apr 20127:00 amRNSInterim Management Statement
26th Apr 20127:00 amRNSFinal Results
25th Apr 20129:13 amRNSNotice of Results
29th Mar 20127:00 amRNSAppointment of New Chairman and Board Changes
13th Feb 20127:00 amRNSNotification of Director's Details
3rd Feb 20123:22 pmRNSDirectors dealings and share option grants
2nd Feb 20124:59 pmRNSBlocklisting Interim Review
1st Feb 20127:02 amRNSBBSRC Industrial Partner Award
1st Feb 20127:01 amRNSDirectorate Change
1st Feb 20127:00 amRNSPre-Close Trading Update
17th Jan 20127:00 amRNSPuriCore Aqualox EPA confirmation
3rd Jan 20127:00 amRNSRaises $3.5 Million Debt Facility
30th Dec 201110:45 amRNSTotal Voting Rights
19th Dec 20118:31 amRNSPuriCore Receives Two Major Contracts-Replacement
19th Dec 20117:54 amRNSPuriCore Receives Two Major Contracts
14th Dec 20117:00 amRNSAgriculture System Confirmed for Use by EPA
13th Dec 201112:44 pmRNSConvertible loan notes extension
18th Nov 20113:42 pmRNSInterim Management Statement
21st Oct 201111:57 amRNSConvertible Loan Notes Update
10th Oct 20118:21 amRNSHolding(s) in Company
22nd Sep 20114:35 pmRNSBoard and Organisational Changes
16th Sep 201111:19 amRNSNew $1.9million Debt Facility Agreed
5th Sep 20114:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.